Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer
Heart BMJ
APRIL 15, 2024
Methods Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab±anthracycline ≥5 years previously were identified from a clinical database. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. years (range 5.9–10.8
Let's personalize your content